Temporary Portal Vein Bypass for Resection of Pancreatic Neoplasms

医学 胰腺切除术 围手术期 外科 肠系膜上静脉 胰腺癌 门静脉 切除术 癌症 内科学
作者
Max Heckler,Sanusi Abdallah,Benedict Kinny‐Köster,Christoph Berchtold,Mohammed Al‐Saeedi,Arianeb Mehrabi,Thilo Hackert,Ulf Hinz,Thomas Hank,Christoph Michalski,Markus W. Büchler,Martin Loos
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
标识
DOI:10.1097/sla.0000000000006662
摘要

Objective: We analyzed perioperative outcomes of patients undergoing pancreatectomy with portal vein resection for pancreatic cancer using temporary intraoperative mesoportal or mesocaval bypass. Summary Background Data: Pancreatectomy for advanced pancreatic cancer with long-segment involvement or complete occlusion of the mesoportal venous axis and cavernous transformation represents a major technical challenge. To avoid major bleeding as well as to overcome severe bowel congestion or ischemia due to long portal venous clamping, a mesoportal or mesocaval venous bypass graft first approach has been proposed. If an additional hepatic arterial resection needs to be considered, the mesoportal bypass seems preferable to ensure portal venous flow avoiding complete temporary vascular exclusion of the liver. However, the mesocaval approach appears to be a technically easier alternative. Methods: All consecutive patients who underwent pancreatectomy with venous bypass were identified from a prospectively maintained database. Patient characteristics, perioperative data, and postoperative short-term outcomes were analyzed. Results: Between 2011 and 2024, 63 patients were operated with temporary construction of an alloplastic venous bypass, including 34 patients with mesoportal and 29 patients with mesocaval bypass. Severe complications (Clavien-Dindo >3a) occurred in 16 of 63 patients (25.4%). No postoperative liver failure was observed. The median length of ICU and hospital stays were 2 and 21 days, respectively. The 90-day mortality rate was 6.3%. There were no differences in complication rates, median length of stays, and 90-day mortality rates between mesoportal and mesocaval shunts. Conclusions: Temporary intraoperative venous bypass graft first techniques are important surgical approaches for safe resection of advanced pancreatic tumors. Mesoportal and mesocaval shunts are both safe with comparable postoperative morbidity and mortality rates. The decision for mesoportal versus mesocaval bypass should be made according to the anatomy, particularly taking into account the extent of arterial involvement and the potential need for concomitant arterial resection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
77777完成签到,获得积分10
2秒前
九日完成签到,获得积分10
3秒前
皮蛋s周关注了科研通微信公众号
3秒前
yys完成签到,获得积分10
3秒前
FashionBoy应助司徒恋风采纳,获得10
3秒前
3秒前
所所应助李静霆采纳,获得30
4秒前
QXH发布了新的文献求助10
4秒前
4秒前
5秒前
wisdom应助Forest1sland采纳,获得10
5秒前
5秒前
wt9189999完成签到,获得积分10
5秒前
6秒前
慕青应助故意的冰岚采纳,获得10
7秒前
an完成签到,获得积分10
7秒前
7秒前
9秒前
9秒前
111发布了新的文献求助30
9秒前
YY19891219发布了新的文献求助10
10秒前
无花果应助外向盼晴采纳,获得30
10秒前
天天快乐应助fkdbdy采纳,获得30
11秒前
隐形曼青应助QXH采纳,获得10
11秒前
39hpl发布了新的文献求助10
11秒前
12秒前
liujun完成签到,获得积分10
13秒前
13秒前
13秒前
14秒前
14秒前
高大美发布了新的文献求助10
15秒前
22发布了新的文献求助10
16秒前
慕青应助科研茶采纳,获得10
16秒前
39hpl完成签到,获得积分20
17秒前
故意的冰岚完成签到,获得积分20
18秒前
阳光项链发布了新的文献求助10
18秒前
王子语发布了新的文献求助10
18秒前
Sandro完成签到,获得积分10
19秒前
情怀应助three采纳,获得10
19秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
不知道标题是什么 500
Christian Women in Chinese Society: The Anglican Story 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961767
求助须知:如何正确求助?哪些是违规求助? 3508099
关于积分的说明 11139632
捐赠科研通 3240798
什么是DOI,文献DOI怎么找? 1791052
邀请新用户注册赠送积分活动 872720
科研通“疑难数据库(出版商)”最低求助积分说明 803344